Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus

INTRODUCTION: Post-anoxic status epilepticus (PASE) is a frequent neurologic complication following hypoxic-ischemic brain injury in cardiac arrest survivors, for which no definitive treatment exists. Early γ-Aminobutyric Acid (GABA) augmentation using vigabatrin, a GABA-transaminase inhibitor, has been proposed; however, its pharmacokinetics (PK) in this critically ill population are unknown. In this ancillary study of VIGAB-STAT, an open-label feasibility trial of loading dose vigabatrin via enteral tube, we evaluated vigabatrin PK. MATERIALS AND METHODS: Comatose adults with electrographic status epilepticus following return of spontaneous circulation received a loading dose of vigabatrin determined by renal function (creatinine clearance (CrCl) ≥ 50 mL/min, 4500 mg; CrCl 30-50 mL/min, 2250 mg; CrCl < 30 mL/min, 1125 mg). Pharmacokinetic sampling occurred at 0 (pre-dose), 0.5, 1, 2, 3, 6, 12, 24, 48, 72, and 168-h post-dose, and plasma concentrations were quantified using liquid chromatography tandem mass spectrometry. PK parameters were estimated using non-compartmental analysis. RESULTS: Six participants contributed 56 plasma samples. The median (range) age was 62 years (22-68), weight 80.9 kg (57.6-139.9), and four (66.7%) participants were male. Loading doses were evenly distributed: 4500 mg (n = 2), 2250 mg (n = 2), and 1125 mg (n = 2). Time to maximum concentration, maximum concentration, area under the concentration time curve from 0 to 24 h, area under the concentration time curve from 0 to infinity and half-life median (range) values were 2 h (1-3), 38.1 mg/L (16.9-91.8), 431.2 mg*h/L (254.6-979.3), 679.3 mg*h/L (340.3-1156.8), and 16.2 h (9.4-23.9), respectively. CONCLUSIONS: This pioneer vigabatrin PK study in critically ill participants with PASE demonstrated absorption regardless of challenges such as enteral delivery type, co-administration of gastric pH modulators, vasopressors, and anesthetics. Notably, prolonged elimination half-lives and increased exposures were observed.

Authors

Institutions

Publication Details

Journal
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Published
2026-09-11
DOI
https://doi.org/10.1002/phar.70198
Primary Topic
Cardiac Arrest and Resuscitation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus

Katharina M. Busl, Charles A. Peloquin, Ralisa Pop, Carolina B. Maciel et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Cardiac Arrest and Resuscitation
article

Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post‐Anoxic Status Epilepticus

Katharina M. Busl, Charles A. Peloquin, Ralisa Pop, Carolina B. Maciel, Nicole Maranchick, Luciola Martins Frota, Camila Guerrero Miranda, Stephan Eisenschenk, Hector David Meza Comparan, Lawrence J. Hirsch
article en

Abstract

INTRODUCTION: Post-anoxic status epilepticus (PASE) is a frequent neurologic complication following hypoxic-ischemic brain injury in cardiac arrest survivors, for which no definitive treatment exists. Early γ-Aminobutyric Acid (GABA) augmentation using vigabatrin, a GABA-transaminase inhibitor, has been proposed; however, its pharmacokinetics (PK) in this critically ill population are unknown. In this ancillary study of VIGAB-STAT, an open-label feasibility trial of loading dose vigabatrin via enteral tube, we evaluated vigabatrin PK. MATERIALS AND METHODS: Comatose adults with electrographic status epilepticus following return of spontaneous circulation received a loading dose of vigabatrin determined by renal function (creatinine clearance (CrCl) ≥ 50 mL/min, 4500 mg; CrCl 30-50 mL/min, 2250 mg; CrCl < 30 mL/min, 1125 mg). Pharmacokinetic sampling occurred at 0 (pre-dose), 0.5, 1, 2, 3, 6, 12, 24, 48, 72, and 168-h post-dose, and plasma concentrations were quantified using liquid chromatography tandem mass spectrometry. PK parameters were estimated using non-compartmental analysis. RESULTS: Six participants contributed 56 plasma samples. The median (range) age was 62 years (22-68), weight 80.9 kg (57.6-139.9), and four (66.7%) participants were male. Loading doses were evenly distributed: 4500 mg (n = 2), 2250 mg (n = 2), and 1125 mg (n = 2). Time to maximum concentration, maximum concentration, area under the concentration time curve from 0 to 24 h, area under the concentration time curve from 0 to infinity and half-life median (range) values were 2 h (1-3), 38.1 mg/L (16.9-91.8), 431.2 mg*h/L (254.6-979.3), 679.3 mg*h/L (340.3-1156.8), and 16.2 h (9.4-23.9), respectively. CONCLUSIONS: This pioneer vigabatrin PK study in critically ill participants with PASE demonstrated absorption regardless of challenges such as enteral delivery type, co-administration of gastric pH modulators, vasopressors, and anesthetics. Notably, prolonged elimination half-lives and increased exposures were observed.

Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyVol. 46(10)
American Association of Colleges of Pharmacy (US), VA Boston Healthcare System (US), Yale University (US), University of Florida (US), Malcom Randall VA Medical Center (US), Florida College (US)
Good health and well-being
Openalex Percentile: Top 7%
Cardiac Arrest and Resuscitation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.